Cigna Group Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers The Cigna Group for the quarterly period ended March 31, 2026. The Company operates through two primary reportable segments: Evernorth Health Services (pharmacy and specialty care) and Cigna Healthcare (medical and behavioral health). A significant structural change occurred in the prior year with the divestiture of Medicare Advantage and related businesses to Health Care Services Corporation (HCSC) on March 19, 2025, which continues to impact year-over-year comparisons.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $68,494 | $65,502 |
| Shareholders' Net Income | $1,654 | $1,323 |
| Diluted EPS | $6.26 | $4.85 |
| Operating Cash Flow | $1,131 | $1,920 |
| Adjusted Income from Operations | $2,058 | $1,840 |
| Total Debt (Short + Long Term) | $30,900 | $31,463 |
| Cash and Cash Equivalents | $7,040 | $7,676 |
Note: Debt figures derived from Balance Sheet line items (Short-term debt + Long-term debt).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 5% year-over-year. This was driven by an 11% increase in Pharmacy revenues ($54.0B) and a 14% increase in Fees and other revenues ($4.4B). Conversely, Premiums decreased 23% ($9.8B) primarily due to the absence of the divested Medicare Advantage business.
- Profitability: Shareholders' net income rose 25% to $1.65 billion. Adjusted income from operations increased 12% to $2.06 billion. The effective tax rate increased to 18.0% from 14.5%, largely due to the absence of a tax benefit related to the HCSC transaction in the prior year.
- Segment Performance:
- Evernorth Health Services: Adjusted revenues grew 9% to $58.4B. Pre-tax adjusted income increased 2% to $1.5B, with Specialty and Care Services driving growth while Pharmacy Benefit Services faced margin pressure from client initiatives.
- Cigna Healthcare: Adjusted revenues declined 21% to $11.5B due to the HCSC divestiture. However, pre-tax adjusted income surged 18% to $1.5B, reflecting improved margins in U.S. Employer and Individual/Family plans.
- Cash Flow: Operating cash flow decreased 41% to $1.1B, attributed to the Inflation Reduction Act impact, lower insurance liabilities, and timing of receivables. Investing cash outflows increased due to the absence of net proceeds from the HCSC transaction in the prior year.
Guidance, Outlook, and Risks
- Strategic Optimization: The Company incurred $380 million in pre-tax costs related to its enterprise-wide strategic optimization program in Q1 2026, primarily for severance. Total program-to-date costs reached $1.13 billion, with payments expected to conclude by the end of 2026.
- Capital Allocation: The Company paid a quarterly dividend of $1.56 per share. No share repurchases were made in Q1 2026, compared to $1.5 billion in repurchases in Q1 2025. The Company maintains a $6.5 billion revolving credit facility and commercial paper program, both undrawn as of March 31, 2026.
- Risks and Contingencies:
- Regulatory: Ongoing exposure to government regulation, including the Inflation Reduction Act and state insurance guaranty assessments.
- Investment Portfolio: The debt securities portfolio remains in a net unrealized depreciation position due to rising interest rates. Commercial mortgage loans have 25% exposure to the office sector, which faces weak fundamentals, though management does not expect material adverse effects.
- Legal: The Company is subject to routine litigation, regulatory inquiries, and False Claims Act investigations inherent to the global health services industry.
Investor Verification Checklist
- HCSC Divestiture Impact: Verify the extent to which Q1 2025 results are non-comparable due to the March 2025 sale of Medicare Advantage businesses.
- Pharmacy Margin Pressure: Review the specific impact of "client- and customer-focused initiatives" and the rebate-free model on Evernorth's Pharmacy Benefit Services margins.
- Strategic Optimization Costs: Confirm the remaining liability for the $1.13 billion optimization program and the timeline for final payments.
- Investment Valuation: Assess the unrealized depreciation in the debt securities portfolio ($437 million) and the credit quality of the commercial mortgage loan portfolio.
- Medical Cost Trend: Monitor the Medical Care Ratio (MCR) in Cigna Healthcare, which improved to 79.8% but remains sensitive to utilization and unit cost trends.